SYRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Spyre Therapeutics Inc (SYRE) is not a strong buy at the moment for a long-term beginner investor. While the company has promising catalysts in its pipeline, such as the SKYLINE trial for ulcerative colitis and the SKYWAY rheumatoid arthritis sub-study, the lack of strong financial performance, insider selling, and no clear proprietary trading signals suggest a cautious approach. The stock may be worth monitoring for future developments, but it is not an immediate buy.
The technical indicators show a bullish trend with the MACD histogram above 0, positively contracting, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). RSI is neutral at 71.173, and the stock is trading near its resistance level of R1: 53.097, suggesting limited immediate upside potential.
The SKYLINE trial for ulcerative colitis and the SKYWAY rheumatoid arthritis sub-study are expected to deliver key clinical data in Q3 2026, which could act as significant growth drivers. Additionally, the company's recent stock option grants reflect confidence in its future growth.
Insider selling has increased by 105.30% over the last month, with the CEO selling 15,000 shares recently. Financial performance remains weak, with negative net income and declining EPS. Additionally, there is no recent congress trading data or strong proprietary trading signals to support a buy decision.
In Q4 2025, the company reported no revenue growth, a net income loss of -$62.53M (up 11.07% YoY), and a drop in EPS to -0.83 (down -18.63% YoY). Gross margin remains at 0%, indicating no significant improvement in financial health.
Stifel analyst Alex Thompson raised the price target to $92 from $70 and maintains a Buy rating, citing the company's potential in the TL1A space for IBD and beyond. However, this optimism is based on future developments rather than current performance.
